Name: Zoom Seminar Series
Start: 2020-09-18T13:30:00-04:00
End: 2020-09-18T14:30:00-04:00
Location: Zoom Seminar Series

The Center for Virology and Vaccine Research (CVVR) at Beth Israel Deaconess Medical Center aims to promote research and education activities related to virology, vaccinology, and related disciplines, including basic, translational, and clinical vaccine research. The Center consists of primary and affiliate faculty and focuses on the development of vaccines against infectious, oncologic, degenerative, and other diseases.

Research Programs

CVVR Clinical Trials

The mission of the CVVR Clinical Trials Unit is the development of novel preventive and therapeutic approaches to viral illnesses such as Human Immunodeficiency Virus (HIV), Zika Virus and COVID-19.

Learn more >

Join the Volunteer Registry

Core Facilities

Flow Cytometry Core

The Flow Cytometry Core facility provides equipment, and consultation and data analysis services by dedicated personnel to both in-house and outside researchers. Areas of expertise include non-human primate (NHP) and infectious disease research. The Flow Cytometry Core is committed to providing the latest software and equipment to better assist peer researchers. The Flow Cytometry Core facility is affiliated with Harvard University and is supported by the NIH Center for AIDS Research (CFAR).
Learn more >

Harvard Catalyst-red on white

Harvard Catalyst Clinical Research Center

The Harvard Catalyst Clinical Research Center (CRC) is a core facility provided to all Beth Isreal Deaconess Medical Center investigators as well as affiliated Harvard faculty for the conduct of clinical trials. The CRC provides contiguous space for inpatient, outpatient, and administrative support activities and is located at BIDMC. CRC staff includes nurses, dieticians, a laboratory assistant, and a unit coordinator. The unit is open for patient activity 24 hours per day, seven days per week.

HIV-1 Neutralizing Antibody Core

The HIV-1 Neutralizing Antibody Core provides in vitro HIV-1 neutralizing antibody assay services to BIDMC and the external research community. The core is GCLP-compliant; it serves as a resource for assessing the breadth and potency of HIV-1 neutralizing antibodies, and for characterizing the neutralization phenotype of HIV-1 isolates.
Learn more >

CVVR Academic Program

In addition to material and technical support, the Center for Virology and Vaccine Research offers a rich intellectual environment for early stage investigators and students. CVVR hosts weekly meetings for its postdoctoral fellows and graduate students to discuss ongoing work, as well as bi-monthly journal club lunches and weekly CVVR seminars with invited speakers. All postdoctoral fellows and junior faculty are encouraged to submit abstracts and to attend conferences and other professional meetings.

Learn more >

Young Investigators

The Young Investigator Committee identifies critical issues affecting young and early career investigators working within CVVR. The Committee connects junior faculty, senior postdoctoral fellows, and other researchers with the goal of building fruitful collaborations, finding solutions to the challenges in research, and developing careers.

Learn more >

Calendar of Events

Fri 21

Zoom Seminar Series

August 21 @ 1:30 pm - 2:30 pm

Fri 28

Zoom Seminar Series

August 28 @ 1:30 pm - 2:30 pm

Sep 04

Zoom Seminar Series

September 4 @ 1:30 pm - 2:30 pm

Sep 11

Zoom Seminar Series

September 11 @ 1:30 pm - 2:30 pm

Sep 18

Zoom Seminar Series

September 18 @ 1:30 pm - 2:30 pm

News and Events

All/CVVR Events/News

2020-08-06/by Morgana Silva

‘Cautious optimism’ – J&J vaccine trials underway

With more than 20 COVID-19 vaccines in clinical trials, the collaboration between Johnson & Johnson and Beth Israel Deaconess in Boston is getting $1 billion in U.S. funding.…

ABCNEWS

2020-08-05/by Morgana Silva

Inside 1 lab’s race to create a COVID19 vaccine

6 companies aside from Johnson & Johnson are in phase 3 of human trials, but the scientists working round the clock at the company’s lab in Boston could see a vaccine by early…

2020-07-30/by Morgana Silva

Johnson & Johnson’s Coronavirus Vaccine Protects Monkeys, Study Finds

An experimental coronavirus vaccine developed by Johnson & Johnson protected monkeys from infection in a new study. It is the second vaccine candidate to show promising results in monkeys…

ABCNEWS

2020-07-30/by Morgana Silva

Johnson & Johnson sees promising COVID-19 vaccine results after testing on monkeys

The pharmaceutical giant will now begin testing its vaccine candidate on humans. Read Article

2020-07-30/by Morgana Silva

Johnson & Johnson starts human study of COVID-19 vaccine after promising monkey data

Johnson & Johnson on Thursday kicked off U.S. human safety trials for its COVID-19 vaccine after releasing details of a study in monkeys that showed its best-performing…

2020-07-30/by Morgana Silva

COVID-19 vaccine developed by Beth Israel, Johnson & Johnson, enters early-stage trials

Dr. Barouch spoke to the Boston Globe about our COVID-19 vaccine developments entering early-stage clinical trial in people. Read Article

2020-07-30/by Morgana Silva

The Latest News About a Promising COVID-19 Vaccine Candidate

Lisa Ling speaks with Dr.Dan Barouch, M.D., Ph.D. about the latest findings in preclinical trials about an investigational #COVID19 vaccine published this morning in Nature and…

HMS

2020-07-28/by Morgana Silva

Vaccines may arrive in record time, but the virus has been faster

Scientists have created candidate vaccines, which eventually could protect billions of people from COVID-19, with astonishing speed, compressing scientific efforts that usually take years into…

2020-07-27/by Morgana Silva

Boston Hospitals Beginning Coronavirus Vaccine Trials

2020-07-26/by Morgana Silva

A covid-19 vaccine can ensure better outcomes for communities of color. Let’s work to earn their trust.

Dr. Kathryn Stephenson co-wrote this OP-ED for the Washington Post. Read Article

2020-07-22/by Morgana Silva

Can You Get Covid-19 Again? It’s Very Unlikely, Experts Say

Researchers are tracking infected monkeys to determine how long this protection lasts. “Durability studies by their nature take time,” said Dr. Dan Barouch. Read Article …

2020-06-18/by Morgana Silva

2020 ID Division Awards

2020-06-12/by Morgana Silva

Secretary Azar, Gov. Charlie Baker, Lt. Gov Polito, and Mass HHS Secretary Sudders visit to BIDMC

Governor Charlie Baker, Lt. Governor Karyn Polito and U.S. Secretary of Health and Human Services Alex Azar joined Dr. Barouch for an important discussion about our COVID-19 vaccine response.…

2019-12-18/by Academic Web Pages

Medical All-Stars

The Boston Red Sox honored Dr.Stephenson on June 7th,2019 as a Medical All-Star for her work in the HIV research field.

2019-12-18/by Academic Web Pages

2019 CVVR Visiting Professor

We were honored to have Dr. Robert Siliciano, MD, PhD. join us for our annual visiting professor this year.

2019-06-25/by Academic Web Pages

2019 Boston Pride Parade

Members of CVVR joined Team BIDMC for the 2019 Boston Pride Parade.

2019-06-18/by Academic Web Pages

2019 Boston AIDS Walk

Members of the CVVR joined TEAM BIDMC for the 2019 Aids Walk, which is the largest HIV/AIDS awareness event in New England.

2019-03-07/by Academic Web Pages

Conference on Retrovirus and Opportunistic Infections 2019

“The annual Conference on Retroviruses and Opportunistic Infections (CROI) brings together top basic, translational, and clinical researchers from around the world to share the latest studies,…

2018-12-18/by Academic Web Pages

2018 Reeves’ Annual Winter Employee Event

2018 Reeve's Annual Winter Employee Event

2018-11-18/by Academic Web Pages

2018 CVVR Visiting Professor

We were honored to have COL. Nelson Michael join us this year as our 2018 visiting professor.

2018-06-03/by Academic Web Pages

2018 AIDS Walk & Run Boston

Dr. Dan Barouch with Mayor Marty Walsh at the Annual 2018 AIDS Walk and Run.

2017-07-07/by Academic Web Pages

Visit from Buckingham Browne & Nichols School

2020-08-06/by Morgana Silva

‘Cautious optimism’ – J&J vaccine trials underway

With more than 20 COVID-19 vaccines in clinical trials, the collaboration between Johnson & Johnson and Beth Israel Deaconess in Boston is getting $1 billion in U.S. funding.…

ABCNEWS

2020-08-05/by Morgana Silva

Inside 1 lab’s race to create a COVID19 vaccine

6 companies aside from Johnson & Johnson are in phase 3 of human trials, but the scientists working round the clock at the company’s lab in Boston could see a vaccine by early…

2020-07-30/by Morgana Silva

Johnson & Johnson’s Coronavirus Vaccine Protects Monkeys, Study Finds

An experimental coronavirus vaccine developed by Johnson & Johnson protected monkeys from infection in a new study. It is the second vaccine candidate to show promising results in monkeys…

ABCNEWS

2020-07-30/by Morgana Silva

Johnson & Johnson sees promising COVID-19 vaccine results after testing on monkeys

The pharmaceutical giant will now begin testing its vaccine candidate on humans. Read Article

2020-07-30/by Morgana Silva

Johnson & Johnson starts human study of COVID-19 vaccine after promising monkey data

Johnson & Johnson on Thursday kicked off U.S. human safety trials for its COVID-19 vaccine after releasing details of a study in monkeys that showed its best-performing…

2020-07-30/by Morgana Silva

COVID-19 vaccine developed by Beth Israel, Johnson & Johnson, enters early-stage trials

Dr. Barouch spoke to the Boston Globe about our COVID-19 vaccine developments entering early-stage clinical trial in people. Read Article

2020-07-30/by Morgana Silva

The Latest News About a Promising COVID-19 Vaccine Candidate

Lisa Ling speaks with Dr.Dan Barouch, M.D., Ph.D. about the latest findings in preclinical trials about an investigational #COVID19 vaccine published this morning in Nature and…

HMS

2020-07-28/by Morgana Silva

Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19).

Lancet, 2018. Read Article

Evidence that CD32a does not mark the HIV-1 latent reservoir.

Nature, 2018. Read Article

Fetal neuropathology in Zika virus-infected pregnant female rhesus monkeys.

Cell, 2018. Read Article

Antibody and TLR7 agonist delay viral rebound in SHIV-infected monkeys

Nature, 2018. Read Article

Zika virus persistence in the central nervous system and lymph nodes of rhesus monkeys.

Cell, 2017. Read Article

Ad26/MVA therapeutic vaccination with TLR7 stimulation in SIV-infected rhesus monkeys.

Nature, 2016. Read Article

Antibody-mediated protection against SHIV challenge includes systemic clearance of distal virus.

Science, 2016. Read Article

Cryo-EM reveals a novel octameric integrase structure for betaretroviral intasome function.

Nature, 2016. Read Article

Protective efficacy of multiple vaccine platforms against Zika virus challenge in rhesus monkeys.

Science, 2016. Read Article

Vaccine protection against Zika virus from Brazil.

Nature, 2016. Read Article

Zika viral dynamics and shedding in rhesus and cynomolgus macaques.

Nat Med., 2016. Read Article

Rapid inflammasome activation following mucosal SIV infection of rhesus monkeys.

Cell, 2016. Read Article

Antigen-specific NK cell memory in rhesus macaques.

Nat. Immunol., 2015. Read Article

Protective efficacy of adenovirus/protein vaccines against SIV challenges in rhesus monkeys.

Science, 2015. Read Article

Rapid seeding of the viral reservoir prior to SIV viraemia in rhesus monkeys

Nature, 2014. Read Article

All Publications >

Research Programs

Neuro-Virology/Immunology

Translational Immunology

Viral Pathogenesis

CVVR Clinical Trials

Core Facilities

Flow Cytometry Core

Harvard Catalyst Clinical Research Center

HIV-1 Neutralizing Antibody Core

CVVR Academic Program

Young Investigators

Calendar of Events

Center for Virology and Vaccine Research

CVVR Clinical Trials Unit

Affiliates